Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2011

View Archived Issues

Novel lysophospholipid S1P1 receptor agonists disclosed

Study confirms associations between IBD and SNPs in newly identified susceptibility genes

Lundbeck presents new dopamine D2 receptor ligands

Spanish CNIO discloses novel agents for treatment of cancer

Merck & Co. presents new HCV NS5B inhibitors

Gilead claims novel inhibitors of Flaviviridae replication

Primera Bioscience's research project with Hospital for Sick Children achieves next major milestones

New serotonin 5-HT6 receptor antagonists prepared by Cephalon

Advaxis completes pre-IND meeting with FDA for prostate cancer immunotherapy

Vertex synthesizes novel PI3K-gamma inhibitors

Bio-Path completes treatment of first cohort of phase I BP-100-1.01 trial

Teijin and Astellas enter agreement for febuxostat

Mologen provides update on ongoing trials of anticancer candidates

Action Pharma completes phase IIb trial of AP-214

Senesco Technologies begins phase Ib/IIa SNS01-T trial

Hybrid malaria vaccine is safe and immunogenic in malaria-exposed Gabonese infants

Pronova BioPharma submits application for phase I trial of omega-3 fatty acid derivative

MannKind confirms with FDA protocols for two Afrezza trials in diabetes

Impax and GSK report topline results from phase III ASCEND-PD study

New animal model allows identification of therapeutic target for primary open-angle glaucoma

TapImmune and Mayo Clinic to conduct phase I trial of breast cancer vaccine

Chugai obtains exclusive Japanese rights to vemurafenib

Starpharma begins phase II study in prevention of bacterial vaginosis

Enrollment begins in phase II study of RGN-259

Phase III trial of Quad regimen meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...